SLC1A4 Antibody

What is SLC1A4 and why is it important in neurodevelopmental research?

SLC1A4 (Solute Carrier Family 1 Member 4) encodes ASCT1, a sodium-dependent neutral amino acid transporter primarily involved in the transport of alanine, serine, cysteine, threonine, proline, and hydroxyproline. This protein is particularly significant in neurodevelopmental research because:

• It mediates L-serine transport from astrocytes to neurons in exchange for D-serine and other amino acid substrates crucial for neuronal survival, growth, and differentiation

• D-serine functions as a physiological coagonist of NMDA receptors, which play essential roles in neurodevelopment, synaptic plasticity, learning, and memory

• Mutations in the SLC1A4 gene have been linked to Spastic Tetraplegia, Thin Corpus Callosum, and Progressive Microcephaly (SPATCCM), a rare autosomal recessive neurodevelopmental disorder

The clinical presentation of SLC1A4-related disorders includes severe global developmental delay, progressive microcephaly, spastic tetraparesis, and in some cases, seizures, underscoring the protein's importance in normal neurological development .

What are the key structural and functional characteristics of SLC1A4/ASCT1 protein?

SLC1A4/ASCT1 protein has several important structural and functional characteristics:

The protein functions primarily as an amino acid exchanger rather than a unidirectional transporter, a characteristic that distinguishes it from some other members of the SLC1 family .

What criteria should be considered when selecting an anti-SLC1A4 antibody for specific research applications?

When selecting an anti-SLC1A4 antibody for your research, consider these criteria:

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IHC, ICC/IF, IP). For example, antibody ab204348 is validated for IHC-P and ICC/IF , while 13067-2-AP is validated for WB, IHC, and IP .

• Species reactivity: Confirm reactivity with your experimental model. Some antibodies like 13067-2-AP react with human, mouse, and rat samples , while others may have more limited cross-reactivity.

• Epitope location: Consider whether targeting specific domains is important for your research. Some antibodies target the C-terminal region (e.g., ab204348 targets aa 450 to C-terminus ), which might be preferable depending on your research questions.

• Antibody type: Polyclonal antibodies often provide higher sensitivity but potentially less specificity than monoclonals. Most commercially available SLC1A4 antibodies are rabbit polyclonals .

• Validation evidence: Review published literature and validation data from manufacturers. For example, antibody 13067-2-AP has been used in multiple publications for Western blot applications .

• Sample preparation compatibility: Consider whether the antibody works with your sample preparation method (e.g., PFA fixation, paraffin embedding).

How can I validate the specificity of an SLC1A4 antibody for my experimental system?

To rigorously validate an SLC1A4 antibody's specificity for your experimental system:

• Genetic validation approaches:

  • Use SLC1A4 knockout/knockdown controls: As demonstrated in zebrafish research, testing the antibody in Slc1a4-deficient samples compared to wild-type is highly effective

  • Overexpression systems: Test antibody in cells overexpressing SLC1A4 versus control cells

• Biochemical validation methods:

  • Western blot analysis: Verify a single band of appropriate molecular weight (62-70 kDa)

  • Immunoprecipitation followed by mass spectrometry: Confirm the identity of the precipitated protein

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide to block specific binding

• Technical validation considerations:

  • Test multiple antibody dilutions to optimize signal-to-noise ratio (e.g., 1:2000-1:10000 for WB, 1:250-1:1000 for IHC)

  • Include tissue-specific positive controls known to express SLC1A4 (brain, kidney)

  • Compare staining patterns across multiple antibodies targeting different epitopes of SLC1A4

• Correlation with orthogonal methods:

  • Compare protein expression with mRNA expression data

  • Correlate immunostaining patterns with in situ hybridization results

What are the optimal protocols for detecting SLC1A4 expression in brain tissue sections?

For optimal detection of SLC1A4 in brain tissue sections, combine these protocol elements based on published methodologies:

For Immunohistochemistry (IHC-P):

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde

  • For paraffin sections: Process as standard, cut 4-6 μm sections

  • For optimal antigen preservation, minimize fixation time to 24-48 hours

• Antigen retrieval (critical for SLC1A4 detection):

  • Primary method: Heat-mediated retrieval using TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Boil paraffin sections for 20 minutes in chosen buffer

• Blocking and antibody incubation:

  • Block with 5% normal serum in PBS with 0.1% Triton X-100 for 1 hour

  • Incubate with primary antibody at optimized concentration:

    • ab204348: 1/20 dilution

    • 13067-2-AP: 1:250-1:1000 dilution

  • Incubate overnight at 4°C for optimal results

• Detection and visualization:

  • Use appropriate HRP-conjugated secondary antibody

  • Develop with DAB substrate

  • Counterstain with hematoxylin for structural context

For Immunofluorescence:

• Sample preparation:

  • For cultured cells: PFA fixation followed by Triton X-100 permeabilization

  • For tissue sections: Follow IHC protocol through primary antibody

  • Example: A431 cells fixed with PFA, permeabilized with Triton X-100

• Antibody concentration:

  • ab204348: 4 μg/ml for immunofluorescence

  • Optimize signal-to-noise ratio for each new experimental system

• Visualization:

  • Use fluorophore-conjugated secondary antibodies

  • Include DAPI nuclear counterstain

  • Mount with anti-fade mounting medium

What are the best practices for using SLC1A4 antibodies in Western blot applications?

For optimal Western blot results when detecting SLC1A4:

Sample preparation:

• Tissue/cell lysis:

  • Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors

  • For brain tissue: Homogenize thoroughly in cold lysis buffer (tissue:buffer ratio of 1:10)

  • For cultured cells: Scrape cells directly in lysis buffer

• Protein quantification:

  • Use BCA Protein Assay Kit to standardize loading

  • Load 20-50 μg total protein per lane

Protocol optimization:

• Gel electrophoresis:

  • Use 10% SDS-PAGE gel for optimal resolution of SLC1A4 (62-70 kDa)

  • Include molecular weight markers that span 50-100 kDa range

• Transfer conditions:

  • Transfer to PVDF membrane (preferred over nitrocellulose for SLC1A4)

  • Transfer at 100V for 60-90 minutes or 30V overnight at 4°C

• Blocking conditions:

  • Block with 5% nonfat milk in TBST for 60 minutes at room temperature

  • Alternative: 5% BSA in TBST if background is problematic

• Antibody incubation:

  • Primary antibody dilutions:

    • 13067-2-AP: 1:2000-1:10000

    • Proteintech anti-Slc1a4: 1:1000

  • Incubate overnight at 4°C for optimal results

  • Secondary antibody: Anti-rabbit IgG-HRP at 1:5000 dilution, 1 hour at room temperature

• Detection system:

  • Use enhanced chemiluminescence (ECL) system

  • Expected molecular weight: 62-70 kDa (may appear as multiple bands due to glycosylation)

Controls and normalization:

• Use appropriate loading controls:

  • GAPDH (36 kDa) or β-tubulin (55 kDa) are suitable

  • Normalize SLC1A4 signal to loading control using densitometry software

How can I address non-specific binding and background issues when using SLC1A4 antibodies?

When encountering non-specific binding and background issues with SLC1A4 antibodies:

For Western blot applications:

• Optimize blocking conditions:

  • Increase blocking time to 2 hours

  • Try alternative blocking agents: switch between 5% milk, 3-5% BSA, or commercial blocking buffers

  • Add 0.05% Tween-20 to reduce hydrophobic interactions

• Antibody optimization:

  • Titrate antibody concentration - start with higher dilutions (1:5000-1:10000) for Western blots

  • Reduce incubation time or increase washing steps (5 x 5 minutes with TBST)

  • Pre-adsorb antibody with liver powder for highly expressed targets

• Sample preparation improvements:

  • Use fresher lysates to minimize protein degradation

  • Centrifuge lysates at high speed to remove cellular debris

For immunohistochemistry/immunofluorescence:

• Background reduction strategies:

  • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce non-specific binding

  • Add 5-10% serum from the species of secondary antibody to block Fc receptors

  • Increase washing duration and frequency between antibody incubations

• Antigen retrieval optimization:

  • Compare TE buffer pH 9.0 vs. citrate buffer pH 6.0 for optimal signal-to-noise ratio

  • Adjust heating time and cooling period

• Antibody-specific approaches:

  • Use more dilute antibody solutions (1:500-1:1000 for IHC)

  • Shorten primary antibody incubation to 2 hours at room temperature instead of overnight

  • Try different secondary antibody systems (polymer-based vs. traditional)

• Tissue-specific considerations:

  • Quench endogenous peroxidase activity with 3% H₂O₂ before blocking

  • For brain tissues with high lipid content, include delipidation steps

  • Use avidin/biotin blocking kit if using biotin-based detection systems

How can SLC1A4 antibodies be used to investigate the relationship between SLC1A4 mutations and neurodevelopmental disorders?

SLC1A4 antibodies can be powerful tools for investigating the relationship between SLC1A4 mutations and neurodevelopmental disorders through these approaches:

Patient-derived sample analysis:

• Compare SLC1A4 protein expression levels and localization in brain samples or patient-derived cells (fibroblasts, iPSCs) from individuals with and without SLC1A4 mutations

• Use immunofluorescence to assess subcellular localization changes in mutant SLC1A4 proteins

• Perform Western blot analysis to determine if protein levels are affected by specific mutations

Model systems for functional characterization:

• Generate cellular models expressing SLC1A4 variants (e.g., R457W, E256K, L315His, S181F) identified in patients with SPATCCM

• Use immunocytochemistry to evaluate trafficking of mutant proteins to the plasma membrane

• Compare WT and mutant protein stability using cycloheximide chase experiments and Western blotting

Studies in developmental contexts:

• Utilize zebrafish models with Slc1a4 mutations to study effects on axon regeneration

• Correlate behavioral phenotypes with protein expression/localization changes

• Employ conditional knockout models with immunohistochemistry to map spatiotemporal requirements for SLC1A4

Pathway analysis and protein interactions:

• Use co-immunoprecipitation with SLC1A4 antibodies to identify interaction partners

• Compare interactomes between wild-type and mutant proteins

• Investigate impacts on downstream signaling using antibodies against phosphorylated proteins in NMDA receptor pathways

Therapeutic development applications:

• Monitor correction of protein expression/localization in gene therapy approaches

• Assess protein level changes in response to treatments targeting serine metabolism

• Use as biomarkers for treatment response in preclinical models

How are SLC1A4 antibodies being used to investigate the role of serine transport in axonal regeneration?

Recent research using SLC1A4 antibodies has revealed important insights into serine transport's role in axonal regeneration:

Methodology and key findings:

In zebrafish models, researchers used SLC1A4 antibodies to:

• Validate genetic models: Confirm successful deletion of Slc1a4 in mutant zebrafish lines using Western blot analysis with anti-Slc1a4 antibodies (normalized to GAPDH or β-tubulin)

• Quantify expression levels: Measure Slc1a4 protein levels in various experimental conditions:

  • Wild-type vs. knockout animals

  • Before vs. after axotomy

  • In neurons overexpressing Slc1a4 vs. controls

• Track regeneration processes: Monitor the relationship between Slc1a4 expression and axonal regeneration outcomes:

  • Results showed that Slc1a4 overexpression significantly enhanced axonal regeneration in Mauthner cells (M-cells)

  • Conversely, Slc1a4 deficiency impeded regeneration processes

Technical approach details:

• Protein detection: Western blot using Slc1a4 antibodies (1:1000 dilution) with visualization by enhanced chemiluminescence system

• Controls: GAPDH (1:2000) or β-tubulin (1:2000) served as loading controls

• Quantification: Band densities were analyzed using ImageJ software and normalized to the loading control

Implications for neurological disease research:

This research connects SLC1A4 function to potential therapeutic strategies for neurological conditions involving axonal damage or regeneration failure, linking serine transport mechanisms directly to regenerative capacity in neurons.

What are the latest methodological advances in using SLC1A4 antibodies to study the pathophysiology of SPATCCM?

Recent methodological advances in using SLC1A4 antibodies to study SPATCCM pathophysiology include:

Combined genetic and protein expression analysis:

Researchers are now employing comprehensive strategies that integrate:

• Whole exome sequencing to identify novel SLC1A4 variants in patients with unexplained developmental delay

• SLC1A4 antibody-based protein analysis to determine functional consequences of identified variants

• Example finding: A novel compound heterozygous variant (c.971delA/c.542C>T) was characterized using expression analysis, showing the maternal c.971delA variant leads to transcript degradation through nonsense-mediated mRNA decay

Structure-function correlation techniques:

• Simulation analysis combined with immunolocalization studies to understand how specific mutations (e.g., S181F missense variant) affect ASCT1 structural confirmation

• Immunocytochemistry to visualize how mutations influence H-bond formation at the core of the protein, potentially affecting transport function

Brain imaging correlation studies:

• Combining MRI findings with immunohistochemical analysis in relevant models

• In recent case reports, brain MRI demonstrating generalized atrophy with thinning of the corpus callosum was correlated with functional studies of SLC1A4 variants

Expanding phenotypic spectrum investigation:

• Using antibodies to investigate SLC1A4 expression in patients with variable presentations:

  • Some with classic triad of spastic tetraplegia, thin corpus callosum, and progressive microcephaly

  • Others with additional features like seizure disorders

  • Cases without epilepsy but with other consistent features

These methodological advances are expanding the understanding of genotype-phenotype correlations in SLC1A4-related disorders, allowing researchers to better characterize the clinical spectrum and underlying molecular mechanisms of SPATCCM.

What are the most reliable antibody validation resources and databases for SLC1A4 research?

For SLC1A4 research, these validated resources provide reliable antibody information:

Public databases and repositories:

• Antibodypedia - Aggregates validation data from multiple sources with user reviews

• Human Protein Atlas - Contains extensive validation data for SLC1A4 antibodies, including immunohistochemistry images across tissues

• RRID Portal (Research Resource Identifiers) - Track validated antibodies by their unique identifiers, such as AB_2190604 for SLC1A4 antibody 13067-2-AP

Manufacturer resources with extensive validation data:

• Cell Signaling Technology - Provides validation data for antibody #8442 including Western blot in human and mouse samples

• Proteintech - Offers detailed application data for antibody 13067-2-AP including positive Western blot results in multiple tissues and cell lines

• Abcam - Provides validation data for ab204348 including immunofluorescence and immunohistochemistry images

Literature validation resources:

Recent publications that have rigorously validated SLC1A4 antibodies include:

• Studies investigating SPATCCM in patients with novel SLC1A4 variants

• Research on Slc1a4's role in axonal regeneration in zebrafish models

When selecting an antibody, cross-reference these resources while considering your specific experimental context and requirements.

How should researchers document and report SLC1A4 antibody use in publications to ensure reproducibility?

To ensure reproducibility in SLC1A4 antibody research, include these comprehensive details in publications:

Antibody identification information:

• Complete catalog number and manufacturer (e.g., Proteintech 13067-2-AP)

• Research Resource Identifier (RRID) when available (e.g., AB_2190604)

• Antibody type (polyclonal/monoclonal) and host species

• Clone identifier for monoclonal antibodies

• Lot number (particularly important for polyclonal antibodies with lot-to-lot variation)

Target specifications:

• Specific epitope or immunogen information (e.g., "SLC1A4 fusion protein Ag3763" or "Recombinant Fragment Protein within Human SLC1A4 aa 450 to C-terminus" )

• Target species and any known cross-reactivity

Detailed methodological parameters:

• Sample preparation methods (fixation type, duration, buffer composition)

• Antibody dilution or concentration used (e.g., "1:2000-1:10000 for WB, 1:250-1:1000 for IHC" )

• Incubation conditions (time, temperature, buffer composition)

• Detection method (fluorescent, chromogenic, chemiluminescent)

• Equipment settings for image acquisition

Validation approaches:

• Positive and negative controls used

• Additional validation experiments performed (knockout controls, peptide competition)

• References to previous validation studies if relying on established antibodies

Results representation:

• Include full, uncropped blot images as supplementary material

• Provide molecular weight markers and loading controls

• Use consistent image processing parameters and document any adjustments

Quantification methods:

• Software used for densitometry or intensity measurements

• Normalization approach (e.g., "normalized to GAPDH or β-tubulin using ImageJ software" )

• Statistical methods for comparing expression levels